REPL - NASDAQ

Replimune Group, Inc.

Replimune Group, Inc.

REPLยทNASDAQ

$10.54

+19%
HealthcareBiotechnology

Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$870.73M
EPS-3.0700
P/E Ratio-3.43
Earnings Date06/04/2026
Replimune Group, Inc.

Replimune Group, Inc. Fair Value Envelope

REPL ยท NASDAQ

Our analysis suggests that REPL has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $10.545, this represents a potential HIDDEN relative to our calculated worth for Replimune Group, Inc..

HIDDEN
Intrinsic Value
Current Price: $10.545

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value-$1.1B
+ Cash & Equivalents$111.1M
Firm Value-$956.3M
- Debt$76.2M
Equity Value-$1.0B
/ Shares Outstanding78,440,135B
DCF Value-$13
OVERVALUED BY 225%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
-$184.4M
-$176.9M
-$169.6M
-$162.7M
-$156.1M
-$149.7M
-$143.6M
-$137.7M
-$132.1M
-$126.7M
Maintenance CapEx
-$1.3M
-$1.2M
-$1.2M
-$1.1M
-$1.1M
-$1.0M
-$998.8K
-$958.0K
-$918.8K
-$881.3K
Owner Earnings
-$185.7M
-$178.1M
-$170.8M
-$163.8M
-$157.1M
-$150.7M
-$144.6M
-$138.7M
-$133.0M
-$127.6M
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
-$171.9M
-$152.7M
-$135.6M
-$120.4M
-$107.0M
-$95.0M
-$84.4M
-$74.9M
-$66.5M
-$59.1M
Terminal Value represents 0.0% of Enterprise Value
Negative Owner Earnings
This company generates negative free cash flow. Consider adjusting maintenance CapEx percentage or check the financial data.

Related Guides

Blog Categories

Continue your REPL research with focused valuation guides.

DCF Modeling

Improve assumptions for intrinsic value accuracy.

Forecasting

Calibrate growth paths and terminal value behavior.

WACC

Refine discount-rate logic for valuation quality.

Cost of Capital

Match risk profile to expected return assumptions.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.